Baxter International Inc. (BAX) Earnings Call Analysis

NYSE · Healthcare · Medical Instruments & Supplies

17/25

Growth 4 Margin 2 Expansion 5 Platform 2 Financial 4

latest quarter score

Earnings Reports

17
Baxter (BAX) Q2 2026: Drug Compounding Delivers Double-Digit Growth, Offsetting Margin Compression
July 30, 2026
11
Baxter (BAX) Q4 2025: Gross Margin Drops 900bps as Mix, Tariffs, and Inventory Weigh on Turnaround
June 15, 2026
12
Baxter (BAX) Q1 2026: Free Cash Flow Swings $297M, Underscoring Turnaround Traction
April 30, 2026
10
Baxter (BAX) Q3 2025: Dividend Slashed to $0.01, Unlocking $300M for Deleveraging
October 30, 2025
8
Baxter (BAX) Q2 2025: Operational Sales Growth Cut to 3% as Novum Pause and Fluid Conservation Extend Headwinds
July 31, 2025
19
Baxter (BAX) Q1 2025: Tariff Exposure Hits $70M, Margin Expansion Still on Track
July 04, 2025
Baxter (BAX) Q3 2024: North Cove Disruption Drives $200M Q4 Sales Hit, Margin Recovery Hinges on Execution
November 08, 2024
Baxter (BAX) Q2 2024: Margin Expands 80bps as Novum and Pharma Drive 4% Growth
August 06, 2024
Baxter (BAX) Q1 2024: Pharmaceuticals Surge 11% as Margin Programs Lift Operating Leverage
May 02, 2024
Baxter (BAX) Q4 2023: $2.8B Debt Paydown Reshapes Capital Allocation Ahead of Kidney Care Spin
February 08, 2024
19
Baxter (BAX) Q3 2023: Operating Margin Rises 200bps Sequentially as Segment Realignment Drives Efficiency
November 02, 2023
Baxter (BAX) Q2 2023: Margin Expansion Path Set by 300bps H2 Operating Leverage
July 27, 2023
Baxter (BAX) Q1 2023: Operating Margin Drops 420 bps as Cost Pressures Persist, Spin-Off Reshapes Portfolio
April 27, 2023

Browse all companies